研究目的:  The goal of this Phase I clinical research study is to determine the tolerable dose of the combination of Afinitor (everolimus) either with Kineret (anakinra) or Xgeva (denosumab) for patients with advanced cancer.  Everolimus is designed to stop cells from dividing.  Anakinra is designated to block a protein that is involved in tumor development, new blood vessels growing, and spread of cancer.  Denosumab is designed to block the activity of a protein, which may prevent bone complications in cancer that has spread to the bone.
赞助商:  M.D. Anderson Cancer Center
试用版联系方式:  Veronica Holley; VRHolley@mdanderson.org Filip Janku; 713-563-1930; FJanku@mdanderson.org
要求患者参与:  ECD patients at least 18 years of age.  Patients may be BRAF positive or negative.
已知参与该试验并接收ECD患者的中心:  MD安德森癌症中心,德克萨斯州休斯顿市
ClinicalTrials.gov 标识符:  NCT01624766